natgillin/translations-raw huggingface dataset:
In a study of ReFacto in children less than 6 years of age, pharmacokinetic analysis revealed half-life and recovery less than that observed in older children and adults (see section 5.2).
V študiji zdravila ReFacto pri otrocih, mlajših od 6 let, je farmakokinetična analiza pokazala razpolovni čas in porast aktivnosti, ki sta bila manjša od tistih, ki so ju ugotovili pri starejših otrocih in odraslih (glejte poglavje 5.2).
In a study of the central nervous system (CNS), bosutinib treated rats displayed decreased pupil size and impaired gait.
V študiji centralnega živčnega sistema (CŽS) so pri podganah, zdravljenih z bosutinibom, opazili zmanjšano velikost zenic in motnje pri hoji.
In a study of toxicity to reproduction and development in rabbits, an increased incidence of post-implantation loss and abortion has been observed at high doses of lipegfilgrastim, likely owing to an exaggerated pharmacodynamic effect specific for rabbits.
V študiji vpliva na sposobnost razmnoževanja in razvoja pri kuncih so pri visokih odmerkih lipegfilgrastima opazili večjo incidenco izgube po ugnezdenju in abortusov, kar je verjetno posledica poudarjenega farmakološkega učinka, ki je specifičen za kunce.
In a study performed in healthy volunteers, netupitant does not affect the exposure of digoxin, a P-gp substrate, whereas it increases its Cmax by fold [90%CI 0.9-1.31].
V študiji z zdravimi prostovoljci netupitant ni vplival na izpostavljenost digoksinu, ki je substrat P-gp, pri čemer pa je povečal njegovo Cmax za 1,09-krat [90 % IZ 0,9-1,31].
In a study performed in patients with severe hepatic impairment (Child- Pugh score 10-12) (n=8), lower plasma concentrations of micafungin and higher plasma concentrations of the hydroxide metabolite (M-5) were seen compared to healthy subjects (n=8).
V študiji, opravljeni pri bolnikih s hudo motnjo v delovanju jeter (stopnja po Child-Pughu 10–12) (n = 8), so v primerjavi z zdravimi preizkušanci opažali nižje plazemske koncentracije mikafungina in višje plazemske koncentracije hidroksidnega presnovka (M-5) (n = 8).
In a study to assess the effects of tadalafil on vision, no impairment of colour discrimination (blue/green) was detected using the Farnsworth Munsell 100 hue test.
V študiji ugotavljanja učinkov tadalafila na vid z uporabo Farnsworth-Munsellovega testa s 100 odtenki niso zaznali nobene okvare razlikovanja barv (modro/zeleno).
In a study using orally administered 14C-memantine, a mean of 84 % of the dose was recovered within 20 days, more than 99 % being excreted renally.
V študiji s peroralnim memantinom, označenim s 14C, se je v 20 dneh izločilo povprečno 84 % odmerka, od tega več kot 99 % prek ledvic.
In a study using orally administered 14C-memantine, a mean of 84 % of the dose was recovered within 20days, more than 99 % being excreted renally.
V študiji peroralnega 14C-memantina se je izločilo 8 4% odmerka v 20 dneh, več kot 99 % preko ledvic.
In a study using orally administered 14C-memantine, a mean of 84 % of the dose was recovered within 20days, more than 99 % being excreted renally.
V študiji peroralnega 14C-memantina se je izločilo 84 % odmerka v 20 dneh, več kot 99 % preko ledvic.
In a study using orally administered 14C-memantine, a mean of 84% of the dose was recovered within 20 days, more than 99% being excreted renally.
V študiji peroralnega 14C-memantina se je izločilo 8 4% odmerka v 20 dneh, več kot 99 % preko ledvic.
In a study using orally administered 14C-memantine, a mean of 84% of the dose was recovered within20 days, more than 99% being excreted renally.
V študiji peroralnega 14C-memantina se je izločilo 84 % odmerka v 20 dneh, več kot 99 % preko ledvic.
In a study using orally administered 14C-memantine, a mean of 84% of the dose was recovered within20 days, more than 99% being excreted renally.
V študiji peroralnega 14C-memantina se je izločilo 84% odmerka v 20 dneh, več kot 99 % preko ledvic.
In a study where 12 subjects with end stage renal disease received a single 500 mg dose of doripenem as a 1-hour i.v. infusion, the systemic exposure to doripenem and doripenem-M-1 were increased compared with healthy subjects.
V študiji z 12 preiskovanci s končno ledvično odpovedjo, ki so z 1-urno intravensko infuzijo prejeli en 500 mg odmerek doripenema, je bila sistemska izpostavljenost doripenemu in doripenemu-M-1 zvečana v primerjavi z zdravimi preiskovanci.
In a study where the dosage form of three 1 mg blisters was compared with one 3 mg blister, Cmax and AUC of inhaling three 1 mg blisters were approximately 30% and 40% greater, respectively, than that of inhaling from one 3 mg blister, indicating that three 1 mg blisters are not interchangeable with one 3 mg blister (see sections 2, 4.2 and 4.4).
V študiji, v kateri so obliko odmerjanja s tremi 1-mg pretisnimi omoti primerjali z enim 3-mg pretisnim omotom, sta bili Cmax in AUC po inhalaciji treh 1-mg pretisnih omotov približno za 30 % in 40 % večji kot po inhalaciji iz enega 3-mg pretisnega omota, kar kaže na to, da trije 1-mg pretisni omoti niso zamenljivi z enim 3- mg pretisnim omotom (glejte poglavja 2, 4.2 in 4.4).
In a study with 18 male subjects with diabetes mellitus type 1 aged 21 to 50 years, insulin glulisine displayed dose-proportional glucose lowering effect in the therapeutic relevant dose range 0.075 to
V študiji z 18 osebami moškega spola z diabetesom mellitusom tipa 1, starimi od 21 do 50 let, je bil učinek insulina glulisin na znižanje glukoze v krvi v razponu terapevtsko pomembnih odmerkov od 0,075 do 0,15 enot/kg sorazmeren z odmerkom.
In a study with 18 male subjects with diabetes mellitus type 1, aged 21 to 50 years, insulin glulisine displays dose-proportionality for early, maximum and total exposure in the dose range
V študiji z 18 osebami moškega spola z diabetesom mellitusom tipa 1, starimi od 21 do 50 let, je bila zgodnja, največja in skupna izpostavljenost insulinu glulisin v razponu odmerkov od 0,075 do
In a study with 18 male subjects with diabetes mellitus type 1, aged 21 to 50 years, insulin glulisine displays dose-proportionality for early, maximum and total exposure in the dose range 0.075 to
V študiji z 18 osebami moškega spola z diabetesom mellitusom tipa 1, starimi od 21 do 50 let, je bila zgodnja, največja in skupna izpostavljenost insulinu glulisin v razponu odmerkov od 0,075 do
In a study with oral immediate release 14C-paliperidone, one week following administration of a single oral dose of 1 mg immediate release 14C-paliperidone, 59% of the dose was excreted unchanged into urine, indicating that paliperidone is not extensively metabolised in the liver.
En teden po uporabi enkratnega peroralnega odmerka 1 mg 14C-paliperidona s takojšnjim sproščanjem se je 59% odmerka izločilo nespremenjenega z urinom, kar kaže, da se paliperidon v jetrih ne presnavlja v veliki meri.
In a study with oral paliperidone in subjects with moderate hepatic impairment (Child-Pugh class B), the plasma concentrations of free paliperidone were similar to those of healthy subjects.
V študiji peroralnega paliperidona pri preizkušancih z zmerno jetrno okvaro (razred B po Child-Pughovi lestvici) so bile koncentracije prostega paliperidona v plazmi podobne kot pri zdravih preizkušancih.
In a study with the seasonal trivalent live attenuated influenza vaccine (T/LAIV), an increased incidence of medically significant wheezing was seen in children 12-23 months of age (see section 4.8).
V študiji s sezonskim trivalentnim cepivom z živim oslabljenim virusom gripe (T/LAIV) so pri otrocih v starosti 12 do 23 mesecev opažali povečano pogostnost zdravstveno pomembnega piskajočega dihanja (glejte poglavje 4.8).
In a sub-study in 13 male alemtuzumab-treated patients (treated with either 12 mg or 24 mg), there was no evidence of aspermia, azoospermia, consistently depressed sperm count, motility disorders or an increase in sperm morphological abnormalities.
V podštudiji s 13 moškimi bolniki, zdravljenimi z alemtuzumabom (zdravljenimi bodisi z 12 mg bodisi s 24 mg), ni bilo dokazov aspermije, azoospermije, stalno zmanjšanega števila spermijev, motenj gibljivosti ali povečanja morfoloških nenormalnosti semenčic.
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to
Pri analizi podskupin glede na vključitveni pogoj (MI, ishemična kap in PAD) je bila korist (doseganje statistične značilnosti pri p = 0,003) največja pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi MI) (zmanjšanje RT: =23,7 %; IZ: 8,9 do 36,2), in manjša (ni bila pomembno drugačna kot pri ASA) pri bolnikih s kapjo (zmanjšanje RT: 7,3 %; IZ: –5,7 do 18,7 /p = 0,258/).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to
Pri analizi podskupin glede na vključitveni pogoj (MI, ishemična kap in PAD) je bila korist (doseganje statistične značilnosti pri p = 0,003) največja pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi MI) (zmanjšanje RT: =23,7%; IZ: 8,9 do 36,2), in manjša (ni bila pomembno drugačna kot pri ASA) pri bolnikih s kapjo (zmanjšanje RT: 7,3%; IZ: –5,7 do 18,7 /p = 0,258/).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to
Pri analizi podskupin glede na vključitveni pogoj (miokardni infarkt, ishemična kap in periferna arterijska bolezen/PAD/) je videti najmočnejšo korist (doseganje statistične značilnosti pri p=0,003) pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi miokardni infarkt) (zmanjšanje RT=23,7 %; IZ: 8,9 do 36,2), in šibkejšo (ni bila pomembno različna od ASA) pri bolnikih s kapjo (zmanjšanje RT=7,3 %; IZ: -5,7 do 18,7 [p=0,258]).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to
Pri analizi podskupin glede na vključitveni pogoj (MI, ishemična kap in PAD) je bila korist (doseganje statistične značilnosti pri p = 0,003) največja pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi MI) (zmanjšanje RT: =23,7 %; IZ: 8,9 do 36,2), in manjša (ni bila pomembno drugačna kot pri ASA) pri bolnikih s kapjo (zmanjšanje RT: 7,3 %; IZ: –5,7 do 18,7 /p = 0,258/).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to
Pri analizi podskupin glede na vključitveni pogoj (MI, ishemična kap in PAD) je bila korist (doseganje statistične značilnosti pri p = 0,003) največja pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi MI) (zmanjšanje RT: =23,7%; IZ: 8,9 do 36,2), in manjša (ni bila pomembno drugačna kot pri ASA) pri bolnikih s kapjo (zmanjšanje RT: 7,3%; IZ: –5,7 do 18,7 /p = 0,258/).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to
Pri analizi podskupin glede na vključitveni pogoj (miokardni infarkt, ishemična kap in periferna arterijska bolezen/PAD/) je videti najmočnejšo korist (doseganje statistične značilnosti pri p=0,003) pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi miokardni infarkt) (zmanjšanje RT=23,7 %; IZ: 8,9 do 36,2), in šibkejšo (ni bila pomembno različna od ASA) pri bolnikih s kapjo (zmanjšanje RT=7,3 %; IZ: -5,7 do 18,7 [p=0,258]).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR=23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR=7.3%; CI: -5.7 to
Pri analizi podskupin glede na vključitveni pogoj (miokardni infarkt, ishemična kap in periferna arterijska bolezen (PAD)) je videti najmočnejšo korist (doseganje statistične značilnosti pri p=0,003) pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi miokardni infarkt) (zmanjšanje RT=23,7 %; IZ: 8,9 do 36,2), in šibkejšo (ni bila značilno različna od acetilsalicilne kisline) pri bolnikih s kapjo (zmanjšanje RT=7,3 %; IZ: -5,7 do 18,7 [p=0,258]).
In a subgroup of 6 subjects, idarucizumab was administered a second time, two months after the first administration.
Podskupini 6 oseb so idarucizumab dajali že drugič dva meseca po prvem dajanju.
In a subgroup of subjects enrolled in this study (10 Respreeza-treated subjects) bronco-alveolar lavage have been performed.
V podskupini oseb, vključenih v to študijo (10 oseb, zdravljenih z zdravilom Respreeza), je bil izveden bronhoalveolarni izpirek.
In a subsequent open-label study (SP824), a multicenter, multinational study, the tolerability of overnight switching from ropinirole, pramipexole or cabergoline to rotigotine transdermal patch and its effect on symptoms in subjects with idiopathic Parkinson’s disease have been studied.
V sledeči odprti študiji (SP824), multicentrični, mednarodni študiji so spremljali prenašanje in učinke na simptome pri bolnikih z idiopatsko Parkinsonovo boleznijo ob nenadni zamenjavi ropinirola, pramipeksola ali kabergolina z rotigotinskim transdermalnim obližem.
In a subsequent study, 217 patients who were treatment- naïve to PDE5 inhibitors were randomized to CIALIS 5 mg once a day vs. placebo.
V nadaljnji študiji so 217 bolnikov, ki se predhodno niso zdravili z zaviralci PDE5, naključno razvrstili v jemanje zdravila CIALIS 5 mg enkrat na dan in jemanje placeba.
In a subsequent study, 217 patients who were treatment-naïve to PDE5 inhibitors were randomized to CIALIS 5 mg once a day vs. placebo.
V nadaljnji študiji so 217 bolnikov, ki se predhodno niso zdravili z zaviralci PDE5, naključno razvrstili v jemanje zdravila CIALIS 5 mg enkrat na dan in jemanje placeba.
In a subset of 1050 patients with moderate to severe hypertension (DBP ≥100 mmHg) 32.7 – 51.8 % responded sufficiently to monotherapy of either telmisartan or amlodipine.
V podskupini 1050 bolnikov z zmerno do hudo hipertenzijo (DKT ≥ 100 mm Hg) je pri 32,7 do 51,8 % bolnikov krvni tlak dovolj znižala monoterapija s telmisartanom ali amlodipinom.
In a subset of 410 patients with ovarian cancer, clinically significant laboratory abnormalities occurring in clinical trials with Caelyx included increases in total bilirubin (usually in patients with liver metastases) (5%) and serum creatinine levels (5%).
V podskupini 410 bolnic z rakom jajčnikov so bili med klinično pomembnimi nenormalnimi laboratorijskimi izvidi, ki so se pojavili v kliničnih preskušanjih z zdravilom Caelyx, zvišanje koncentracije celokupnega bilirubina (običajno pri bolnikih z jetrnimi metastazami) (5%) in serumske koncentracije kreatinina (5%).
In a subset of monkeys, chronic dosing (7 to 26 weekly doses) resulted in episodes of severe secretory diarrhoea.
V podskupini opic je kronična uporaba (od 7 do 26 tedenskih odmerkov) povzročila pojavljanje hude sekretorne diareje.
In a subset of young adult SJIA patients aged 16 to 20 years (n=31), the safety profile of Ilaris was consistent with what was observed in SJIA patients less than 16 years of age.
V podskupini mladih odraslih bolnikov s SJIA, ki so bili stari od 16 do 20 let (n=31), je bil varnostni profil zdravila Ilaris podoben kot pri tistih bolnikih s SJIA, ki so bili stari manj kot 16 let.
In a supplemental analysis, the efficacy of Cervarix was evaluated against HPV-16/18-related CIN3+.
V dodatni analizi so ocenili učinkovitost cepiva Cervarix proti CIN3+, povezanemu s HPV-16/18.
In a supplemental analysis, the efficacy of Silgard was evaluated against HPV 16/18-related CIN 3 and AIS.
Z dodatno analizo je bila ovrednotena še učinkovitost cepiva Silgard proti CIN 3 in AIS zaradi HPV 16/18.
In a supporting study of ReFacto AF, 1 de novo and 2 recurrent inhibitors (all low-titre, central laboratory determination) were observed in 110 patients; median exposure of 58 ED (range 5-140) and 98 patients had at least 50 ED to ReFacto AF.
V podporni študiji zdravila ReFacto AF so pri 110 bolnikih našli 1 primer inhibitorja de novo in 2 recidivna primera inhibitorja (vsi z nizkimi titri, določenimi v centralnem laboratoriju); mediana izpostavljenost je bila 58 ED (razpon 5-140) in 98 bolnikov je imelo vsaj 50 ED zdravilu ReFacto AF.
In a third main study in 846 newly diagnosed patients with chronic phase CML, Tasigna, either as 300 mg twice a day or as 400 mg twice a day, was compared with imatinib.
V tretji glavni študiji, v katero je bilo vključenih 846 bolnikov, pri katerih je bila kronična faza mieloične levkemije ugotovljena na novo, so zdravilo Tasigna, bodisi v odmerku 300 mg dvakrat na dan bodisi 400 mg dvakrat na dan, primerjali z imatinibom.
In a third phase III randomised, double-blind trial, 4 mg zoledronic acid or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion.
V tretjem randomiziranem, dvojno slepem preskušanju faze III so pri bolnicah/bolnikih z multiplim mielomom ali rakom dojke z vsaj po eno lezijo v kosteh primerjali zoledronsko kislino 4 mg in 90 mg pamidronata vsake 3 do 4 tedne.
In a third phase III randomised, double-blind trial, zoledronic acid 4 mg or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion.
V tretji, randomizirani, dvojno slepi študiji faze III so pri bolnicah/bolnikih z multiplim mielomom ali rakom dojke z vsaj po eno lezijo v kosteh primerjali zoledronsko kislino 4 mg in 90 mg pamidronata vsake 3 do 4 tedne.
In a thorough QT interval study of doses of 1.25 or 2.5 mg fingolimod at steady-state, when a negative chronotropic effect of fingolimod was still present, fingolimod treatment resulted in a prolongation of QTcI, with the upper limit of the 90% CI ≤13.0 ms.
V podrobni študiji intervala QT z odmerki 1,25 oziroma 2,5 mg fingolimoda je v stacionarnem stanju v času, ko je bil še vedno prisoten negativni kronotropni učinek zdravila, zdravljenje s fingolimodom povzročilo podaljšanje intervala QTcI (individualno korigiranega intervala QT) z zgornjo mejo 90- odstotnega intervala zaupanja ≤13,0 ms.
In a three-month, controlled clinical study in patients with open-angle glaucoma or ocular hypertension and baseline mean IOP of 27 to 30 mmHg, the mean IOP-lowering effect of DuoTrav dosed once-daily in the morning was 9 to 12 mmHg, and was up to 2 mmHg greater than that of travoprost 40 micrograms/ml dosed once-daily in the evening and 2 to 3 mmHg greater than that of timolol 5 mg/ml dosed twice daily.
V trimesečni kontrolirani klinični študiji pri bolnikih z glavkomom odprtega zakotja ali očesno hipertenzijo ter začetno srednjo vrednostjo očesnega tlaka od 27 do 30 mmHg je bil srednji učinek zdravila DuoTrav, danega enkrat na dan zjutraj, na zmanjšanje očesnega tlaka od 9 do 12 mmHg in je bil za do 2 mmHg večji od učinka travoprosta 40 mikrogramov/ml, danega enkrat na dan zvečer, in za 2 do 3 mmHg večji od učinka timolola 5 mg/ml, danega dvakrat na dan.
In a total of 555 patients, the median baseline percent predicted FVC and
Od skupaj 555 bolnikov je bila mediana predvidene forsirane vitalne kapacitete 68 % (razpon: 48–91 %) in difuzijska kapaciteta za CO
In a total of four clinical trials, approximately 3800 doses of Rotarix liquid formulation were administered to approximately 1900 infants.
V skupaj štirih kliničnih preskušanjih so uporabili približno 3800 odmerkov tekoče oblike cepiva Rotarix pri približno 1900 dojenčkih.
In a total of twenty-three clinical trials, approximately 106000 doses of Rotarix (lyophilised or liquid formulation) were administered to approximately 51000 infants.
Izvedenih je bilo triindvajset kliničnih preskušanj, v katerih je približno 51000 otrok prejelo približno 106000 odmerkov cepiva Rotarix (liofilizirana ali tekoča oblika).
In a total of twenty-three clinical trials, approximately 106000 doses of Rotarix (lyophilised or liquid formulation) were administered to approximately 51000 infants.
Izvedenih je bilo triindvajset nadzorovanih kliničnih preskušanj, v katerih je približno 51000 otrok prejelo približno 106000 odmerkov cepiva Rotarix (liofilizirana ali tekoča oblika).
In a treatment cycle, Dacogen is administered at a dose of 20 mg/m2 body surface area by intravenous infusion over 1 hour repeated daily for 5 consecutive days (i.e., a total of 5 doses per treatment cycle).
V enem krogu zdravljenja se zdravilo Dacogen aplicira v odmerku 20 mg/m2 telesne površine z intravensko infuzijo, ki traja najmanj 1 uro, in sicer 5 zaporednih dni (torej skupno 5 odmerkov v enem krogu zdravljenja).
In a trial designed to assess discontinuation symptoms by the Discontinuation Emergent Signs and Symptoms (DESS) check-list in patients with remitted depression, Thymanax did not induce discontinuation syndrome after abrupt treatment cessation.
V preskušanju, kjer so s pomočjo vprašalnika o pojavljanju znakov in simptomov po odtegnitvi (DESS – Discontinuation Emergent Signs and Symptoms) ocenjevali odtegnitvene simptome pri bolnikih z remisijo depresije, zdravilo Thymanax ni povzročalo odtegnitvenega sindroma po nenadni prekinitvi zdravljenja.
In a trial designed to assess discontinuation symptoms by the Discontinuation Emergent Signs and Symptoms (DESS) check-list in patients with remitted depression, Valdoxan did not induce discontinuation syndrome after abrupt treatment cessation.
V preskušanju, kjer so s pomočjo vprašalnika o pojavljanju znakov in simptomov po odtegnitvi (DESS – Discontinuation Emergent Signs and Symptoms) ocenjevali odtegnitvene simptome pri bolnikih z remisijo depresije, zdravilo Valdoxan ni povzročalo odtegnitvenega sindroma po nenadni prekinitvi zdravljenja.
In a trial of patients with persistent, recurrent or metastatic cervical cancer, the incidence of GI-vaginal fistulae was 8.3% in Avastin-treated patients and 0.9% in control patients, all of whom had a history of prior pelvic radiation.
V preskušanju pri bolnicah z rakom materničnega vratu, pri katerih je bila bolezen prisotna tudi po zaključenem primarnem zdravljenju, se je ponovila ali je bila metastatska, je bila incidenca fistul med prebavili in nožnico 8,3 % med prejemnicami zdravila Avastin in 0,9 % pri bolnicah v kontrolni skupini; vse te bolnice so imele v anamnezi obsevanje medeničnega predela.